Trials / Conditions / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

14 registered clinical trials studyying Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cel NCT07278856	City of Hope Medical Center	Phase 1
Suspended	Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma NCT04803201	Alliance for Clinical Trials in Oncology	Phase 2
Completed	Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Ma NCT02342782	City of Hope Medical Center	Phase 1
Recruiting	Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma NCT03501576	Emory University	—
Active Not Recruiting	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lym NCT03113500	City of Hope Medical Center	Phase 2
Active Not Recruiting	Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Trans NCT02797470	AIDS Malignancy Consortium	Phase 1 / Phase 2
Active Not Recruiting	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency NCT01787409	Mayo Clinic	N/A
Completed	Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-C NCT01567709	National Cancer Institute (NCI)	Phase 1
Completed	Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma NCT01466881	National Cancer Institute (NCI)	Phase 2
Completed	Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating You NCT01403415	National Cancer Institute (NCI)	Phase 1
Completed	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma NCT01326702	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578	National Cancer Institute (NCI)	Phase 1
Completed	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361	National Cancer Institute (NCI)	Phase 1
Completed	Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma NCT00082888	National Cancer Institute (NCI)	Phase 2